## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

## LISTING OF CLAIMS

 (previously presented) A micronutrient combination product comprising: 0.1-2 mg of zeaxanthin, 2-40 mg of lutein, 2-80 mg of zinc, and 0.02-2 mg of copper, wherein the micronutrient combination product is free of beta-carotene, and comprises a daily dosage administrable to a subject.

## (canceled)

- (previously presented) The micronutrient combination product according to claim 1, further comprising at least one vitamin selected from the group consisting of vitamin C, vitamin E, and combinations thereof.
- 4. (previously presented) The micronutrient combination product according to claim 3, wherein said vitamin C is in an amount of 50-500 mg, and said vitamin E is in an amount of 2-60 mg.
- (previously presented) The micronutrient combination product according to claim 1, wherein the micronutrient combination product is a solid, a liquid, or a gel.
- (previously presented) The micronutrient combination product according to claim 1, wherein the micronutrient combination product is a solid having a core of from 200 mg to 1000 mg.
- 7. (previously presented) The micronutrient combination product according to claim 1, further comprising an adjuvant selected from the group consisting of lactose, povidone, cellulose, cellulose derivatives, microcrystalline cellulose, starch, starch derivatives, magnesium stearate, stearic acid, gelatin, sodium aluminum silicate, silica, maltodextrin, dextrose, talcum, titanium dioxide, calcium carbonate, vegetable fats, tricalcium phosphate,

Serial No. 10/583,953

antioxidants, stabilizers, Arabic gum, calcium phosphates, calcium silicate, sucrose, sodium citrate, citric acid, and gustatory corrigents.

- 8. (previously presented) The micronutrient combination product according to claim 1, further comprising a coating substance selected from the group comprising cellulose, cellulose derivatives, hydroxypropyl cellulose, hydroxypropyl methylcellulose, and/er microcrystalline cellulose, titanium dioxide, dyes, talcum, polymethacrylates, shellac, polyvinylpyrrolidone, polyvinyl alcohol, polyethylene glycols, triacetin, triethyl citrate, propylene glycol, glycerol, Arabic gum, silica, glycerol monostearate, and and/er cotton seed oil.
- 9. (previously presented) The micronutrient combination product according to claim 7, wherein said zinc comprises zinc gluconate, said copper comprises copper (II) gluconate, said vitamin E comprises vitamin E acetate, said vitamin C comprises ascorbic acid, and said adjuvant comprises cellulose, lactose, or magnesium stearate.
- 10. (currently amended) The micronutrient combination product according to claim 1, wherein the micronutrient combination product is one daily dose consisting of:

[[a.]] 12 mg lutein;
[[b.]] 0.6 mg zeaxanthin;
[[c.]] 150 mg vitamin C;
[[d.]] 15 mg vitamin E;
[[e.]] 0.4 mg copper;
[[f.]] 20 mg zinc; and
[[g.]] an adjuvant.

11. (currently amended) The micronutrient combination product according to claim 1, wherein the micronutrient combination product is one daily dose consisting of two units, each unit consisting of:

- [[e.]] 0.2 mg copper;
- [[f.]] 10 mg zinc; and
- [[g.]] an adjuvant.
- 12. (withdrawn) A process for manufacturing a micronutrient combination product, the process comprising: (a) preparing a mixture comprising zeaxanthin, lutein, zinc, copper, and an adjuvant; and (b) forming the mixture into a daily dosage unit, wherein said mixture is free of beta-carotene, and wherein said zeaxanthin in said daily dosage unit is present in an amount of 0.1-2 mg, said lutein in said daily dosage unit is present in an amount of 2-40 mg, said zinc in said daily dosage unit is present in an amount of 2-80 mg, and said copper in said daily dosage unit is present in an amount of 0.02-2 mg.
- 13. (withdrawn) A method of supplementing a balanced diet of a subject, said method comprising administering to said subject a micronutrient combination product of claim 1.
- 14. (withdrawn) The method of claim 13, wherein said subject is at risk of developing age-related macular degeneration.